Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 13/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MERTK | Q12866 | 3/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945948 | 0.89 | MERTK (0.40) | SLC34A1MERTKPTGIR | |
| SCHEMBL391590 | 0.87 | PTGIR (0.51) | SLC34A1PTGS2MERTKPTGIR | |
| SCHEMBL3938976 | 0.83 | PTGIR (0.50) | SLC34A1PTGS2PTGIR | |
| SCHEMBL390854 | 0.80 | MAPK13 (0.40) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL393826 | 0.78 | PTGIR (0.48) | SLC34A1MERTKPTGIRAXLTYRO3 | |
| SCHEMBL393821 | 0.77 | ALDH1A1 (0.43) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL393814 | 0.76 | ALDH1A1 (0.38) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3938997 | 0.76 | PTGIR (0.44) | SLC34A1MERTKPTGIR | |
| SCHEMBL3942256 | 0.74 | KCNK3 (0.39) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL392878 | 0.72 | PTGIR (0.48) | SLC34A1PTGS2MERTKPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101207-B2 | Composition containing medicine extremely slightly soluble in water and method for preparation thereof | KOWA CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1043317-B1 | PYRIDAZINE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS ACTIVE INGREDIENT | KOWA CO (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-2017266-A1 | Pyridazine derivatives and medicines containing the same as effective ingredients | Kowa Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2002-09-05 | — | — | US | disclosed |
| US-6348468-B1 | THESE COMPOUNDS HAVE EXCELLENT INHIBITORY ACTIVITY AGAINST INTERLEUKIN-1.BETA. PRODUCTION, IMMUNE SYSTEM DISEASES, INFLAMMATORY DISEASES, ISCHEMIC DISEASES AND THE LIKE. | KOWA CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1043317-A1 | NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Kowa Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | SLC34A1 3309/4885PTGS2 28/4885MERTK 1138/4885 |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IL1R1, IRAK1 | SLC34A1 3502/4885PTGS2 31/4885MERTK 785/4885 |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | SLC34A1 3345/4885PTGS2 31/4885MERTK 1068/4885 |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | SLC34A1 3332/4885PTGS2 28/4885MERTK 938/4885 |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | SLC34A1 2904/4885PTGS2 26/4885MERTK 1040/4885 |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | SLC34A1 3332/4885PTGS2 28/4885MERTK 938/4885 |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | SLC34A1 3332/4885PTGS2 28/4885MERTK 938/4885 |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | SLC34A1 3345/4885PTGS2 31/4885MERTK 1068/4885 |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | SLC34A1 2904/4885PTGS2 26/4885MERTK 1040/4885 |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | SLC34A1 3309/4885PTGS2 28/4885MERTK 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.